What's Going On With TG Therapeutics Stock Wednesday?
Portfolio Pulse from Dylan Berman
TG Therapeutics, Inc. (NASDAQ:TGTX) stock is trading higher after the company updated its data presentations from the ULTIMATE I & II Phase 3 trials of BRIUMVI for multiple sclerosis. The data showed reduced relapse rates and stable safety over five years.
September 18, 2024 | 2:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TG Therapeutics' stock is up 1.52% following positive data from Phase 3 trials of BRIUMVI, showing reduced relapse rates and stable safety in MS patients over five years.
The positive data from the Phase 3 trials of BRIUMVI, showing reduced relapse rates and stable safety, is likely to boost investor confidence in TG Therapeutics, leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100